

Theresa L Whiteside

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1108720/publications.pdf>

Version: 2024-02-01

255
papers

22,912
citations

6233

80
h-index

9553

142
g-index

261
all docs

261
docs citations

261
times ranked

24008
citing authors

#	ARTICLE	IF	CITATIONS
1	The tumor microenvironment and its role in promoting tumor growth. <i>Oncogene</i> , 2008, 27, 5904-5912.	2.6	1,869
2	Tumor-Derived Exosomes and Their Role in Cancer Progression. <i>Advances in Clinical Chemistry</i> , 2016, 74, 103-141.	1.8	549
3	Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes. <i>Journal of Immunology</i> , 2009, 183, 3720-3730.	0.4	479
4	Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 896-905.	3.2	464
5	Exosomes and tumor-mediated immune suppression. <i>Journal of Clinical Investigation</i> , 2016, 126, 1216-1223.	3.9	439
6	Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. <i>Seminars in Cancer Biology</i> , 2006, 16, 3-15.	4.3	410
7	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
8	A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor- β 1 Mediates Suppression in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2007, 13, 4345-4354.	3.2	393
9	Tumor-Derived Microvesicles Induce, Expand and Up-Regulate Biological Activities of Human Regulatory T Cells (Treg). <i>PLoS ONE</i> , 2010, 5, e11469.	1.1	379
10	Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- β 1. <i>Haematologica</i> , 2011, 96, 1302-1309.	1.7	375
11	Isolation of biologically-active exosomes from human plasma. <i>Journal of Immunological Methods</i> , 2014, 411, 55-65.	0.6	363
12	Lymphocytes in the skin of patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1984, 27, 645-653.	6.7	356
13	Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). <i>Biochemical Society Transactions</i> , 2013, 41, 245-251.	1.6	341
14	Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. <i>Clinical Cancer Research</i> , 2005, 11, 1010-20.	3.2	337
15	Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+ Regulatory T Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 7176-7186.	1.6	334
16	The microbiome in autoimmune diseases. <i>Clinical and Experimental Immunology</i> , 2018, 195, 74-85.	1.1	311
17	Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4843-4854.	3.2	275
18	Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. <i>Clinical Cancer Research</i> , 2002, 8, 2553-62.	3.2	275

#	ARTICLE	IF	CITATIONS
19	Challenges in Exosome Isolation and Analysis in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4684.	1.8	261
20	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. <i>Scientific Reports</i> , 2016, 6, 20254.	1.6	260
21	Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. <i>Human Gene Therapy</i> , 1996, 7, 1261-1280.	1.4	254
22	Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 29289.	5.5	249
23	The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2007, 13, 6301-6311.	3.2	244
24	Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2629-2635.	2.9	243
25	What are regulatory T cells (Treg) regulating in cancer and why?. <i>Seminars in Cancer Biology</i> , 2012, 22, 327-334.	4.3	242
26	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
27	Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4407.	1.8	236
28	Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. <i>Seminars in Immunology</i> , 2018, 35, 69-79.	2.7	233
29	Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. <i>Clinical and Experimental Immunology</i> , 2014, 177, 531-543.	1.1	220
30	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	217
31	Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1435138.	5.5	210
32	Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection. <i>Head and Neck</i> , 2007, 29, 163-188.	0.9	209
33	Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. <i>Cancer Research</i> , 1989, 49, 5167-75.	0.4	201
34	Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3890-3895.	3.2	200
35	T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. <i>Clinical Cancer Research</i> , 2003, 9, 5113-9.	3.2	195
36	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3000.	5.8	194

#	ARTICLE	IF	CITATIONS
37	Plasma Exosomes as Markers of Therapeutic Response in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2014, 5, 160.	2.2	187
38	The emerging roles of tumor-derived exosomes in hematological malignancies. <i>Leukemia</i> , 2017, 31, 1259-1268.	3.3	178
39	Human Circulating CD4+CD25highFoxp3+ Regulatory T Cells Kill Autologous CD8+ but Not CD4+ Responder Cells by Fas-Mediated Apoptosis. <i>Journal of Immunology</i> , 2009, 182, 1469-1480.	0.4	171
40	Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assay. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 102-114.	0.9	170
41	Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. <i>Cancer Research</i> , 1999, 59, 5356-64.	0.4	168
42	Activation of Raf by ionizing radiation. <i>Nature</i> , 1996, 382, 813-816.	13.7	162
43	Immune responses to malignancies. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, S272-S283.	1.5	160
44	Isolation and Characterization of CD34+ Blast-Derived Exosomes in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e103310.	1.1	155
45	Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. <i>Scientific Reports</i> , 2017, 7, 14684.	1.6	152
46	Signaling defects in T lymphocytes of patients with malignancy. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 346-352.	2.0	148
47	The number of intratumoral dendritic cells and γ -chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. <i>Cancer</i> , 2001, 91, 2136-2147.	2.0	145
48	Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 67-72.	2.0	144
49	T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease. <i>Clinical Cancer Research</i> , 2008, 14, 3706-3715.	3.2	143
50	Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. <i>Oncolmmunology</i> , 2017, 6, e1261243.	2.1	143
51	Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. <i>Molecular Cancer Research</i> , 2018, 16, 1798-1808.	1.5	143
52	Adenosine and Prostaglandin E2 Cooperate in the Suppression of Immune Responses Mediated by Adaptive Regulatory T Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 27571-27580.	1.6	140
53	Expansion of Human T Regulatory Type 1 Cells in the Microenvironment of Cyclooxygenase 2 Overexpressing Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2007, 67, 8865-8873.	0.4	136
54	Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. <i>Scientific Reports</i> , 2018, 8, 12905.	1.6	135

#	ARTICLE	IF	CITATIONS
55	Down-regulation of γ -chain expression in T cells: a biomarker of prognosis in cancer?. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 865-78.	2.0	134
56	Tumor-induced death of immune cells: its mechanisms and consequences. <i>Seminars in Cancer Biology</i> , 2002, 12, 43-50.	4.3	131
57	Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. <i>International Journal of Cancer</i> , 1986, 37, 803-811.	2.3	129
58	Exosomes carrying immunoinhibitory proteins and their role in cancer. <i>Clinical and Experimental Immunology</i> , 2017, 189, 259-267.	1.1	127
59	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	126
60	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. <i>Cancer Cell</i> , 2019, 35, 33-45.e6.	7.7	125
61	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , 2020, 10, 92.	1.6	122
62	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
63	FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 353-363.	1.5	119
64	The potential of tumor-derived exosomes for noninvasive cancer monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1293-1310.	1.5	117
65	Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 354-365.	1.6	114
66	The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. <i>Future Oncology</i> , 2017, 13, 2583-2592.	1.1	113
67	Natural Killer Cells and Tumor Therapy. <i>Current Topics in Microbiology and Immunology</i> , 1998, 230, 221-244.	0.7	111
68	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. <i>Oncolmmunology</i> , 2019, 8, e1593805.	2.1	110
69	Human Tumor-Derived vs Dendritic Cell-Derived Exosomes Have Distinct Biologic Roles and Molecular Profiles. <i>Immunologic Research</i> , 2006, 36, 247-254.	1.3	109
70	Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2013, s4, 3.	0.1	109
71	The role of Fas/FasL in immunosuppression induced by human tumors. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 175-184.	2.0	108
72	Phenotypic and functional characteristics of CD4 ⁺ CD39 ⁺ FOXP3 ⁺ and CD4 ⁺ CD39 ⁺ FOXP3 ^{neg} T ϵ cell subsets in cancer patients. <i>European Journal of Immunology</i> , 2012, 42, 1876-1885.	1.6	99

#	ARTICLE	IF	CITATIONS
73	Phenotypic and functional characteristics of CD39 ^{high} human regulatory B cells (Breg). <i>Oncolmmunology</i> , 2016, 5, e1082703.	2.1	99
74	The role of regulatory T cells in cancer immunology. <i>ImmunoTargets and Therapy</i> , 2015, 4, 159.	2.7	96
75	Potential roles of tumor-derived exosomes in angiogenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 409-417.	1.5	93
76	Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. <i>Oncolmmunology</i> , 2015, 4, e1008347.	2.1	91
77	Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6585-6596.	3.2	90
78	Clinical and serologic study of sjögren's syndrome in patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983, 26, 500-508.	6.7	89
79	Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. <i>Head and Neck</i> , 2009, 31, 371-380.	0.9	89
80	Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells. <i>Journal of Immunology</i> , 2004, 173, 1526-1534.	0.4	86
81	Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1429-1442.	2.0	82
82	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. , 1996, 68, 276-284.		81
83	Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. <i>Clinical and Experimental Immunology</i> , 2018, 194, 67-78.	1.1	81
84	Suppressor cell function and t lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983, 26, 841-847.	6.7	79
85	Separation of plasma-derived exosomes into CD3(+) and CD3(âˆ) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. <i>Clinical and Experimental Immunology</i> , 2018, 192, 271-283.	1.1	78
86	Induced regulatory T cells in inhibitory microenvironments created by cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1411-1425.	1.4	76
87	Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. <i>Cancer Research</i> , 1993, 53, 5654-62.	0.4	76
88	Information transfer by exosomes: A new frontier in hematologic malignancies. <i>Blood Reviews</i> , 2015, 29, 281-290.	2.8	74
89	Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multi-peptide vaccine in patients with melanoma. <i>Clinical Cancer Research</i> , 2003, 9, 641-9.	3.2	74
90	Tumor-derived exosomes promote angiogenesis via adenosine A2B receptor signaling. <i>Angiogenesis</i> , 2020, 23, 599-610.	3.7	73

#	ARTICLE	IF	CITATIONS
91	Head and Neck Carcinoma Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 6-13.	3.2	71
92	Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis?. <i>Frontiers in Oncology</i> , 2013, 3, 107.	1.3	70
93	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1157-1168.	0.6	69
94	Analysis of Intestinal Lymphocyte Subpopulations in Patients with Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex. <i>American Journal of Clinical Pathology</i> , 1987, 87, 356-364.	0.4	68
95	IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. <i>Cell Death and Differentiation</i> , 2009, 16, 708-718.	5.0	67
96	Targeting adenosine in cancer immunotherapy: a review of recent progress. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 527-535.	1.1	67
97	Optimization of cell culture conditions for exosome isolation using mini-size exclusion chromatography (mini-SEC). <i>Experimental Cell Research</i> , 2019, 378, 149-157.	1.2	66
98	Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. <i>Cancer Immunology, Immunotherapy</i> , 1988, 26, 1-10.	2.0	63
99	Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. <i>Hepatology</i> , 1992, 15, 816-823.	3.6	63
100	Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading. <i>Immunological Investigations</i> , 2000, 29, 121-125.	1.0	61
101	CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4 ⁺ T effector cells in patients with head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2012, 1, 659-669.	2.1	60
102	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020, 41, 625-633.	1.3	60
103	Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression. <i>Vaccines</i> , 2016, 4, 35.	2.1	59
104	Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3990.	1.8	59
105	Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1985, 28, 188-197.	6.7	58
106	Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. <i>European Journal of Immunology</i> , 1998, 28, 780-786.	1.6	58
107	Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 81-89.	0.8	55
108	Chromosomal breakpoints in cholangiocarcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 1990, 2, 300-310.	1.5	53

#	ARTICLE	IF	CITATIONS
109	Adenosine and Prostaglandin E2 Production by Human Inducible Regulatory T Cells in Health and Disease. <i>Frontiers in Immunology</i> , 2013, 4, 212.	2.2	53
110	CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2019, 467, 85-95.	3.2	53
111	Isolation and Analysis of Tumor-Derived Exosomes. <i>Current Protocols in Immunology</i> , 2019, 127, e91.	3.6	52
112	Evaluation of Exosome Proteins by on-Bead Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 372-381.	1.1	52
113	Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. <i>Cytometry</i> , 2000, 41, 321-328.	1.8	50
114	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(âˆ“) Head and Neck Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2018, 8, 445.	1.3	50
115	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016, 130, 517-527.	1.4	49
116	Cytokines and cytokine measurements in a clinical laboratory. <i>Vaccine Journal</i> , 1994, 1, 257-260.	2.6	46
117	The Role of Death Receptor Ligands in Shaping Tumor Microenvironment. <i>Immunological Investigations</i> , 2007, 36, 25-46.	1.0	44
118	Immunodiagnosis of mesothelioma. Use of antimesothelial cell serum in an indirect immunofluorescence assay. <i>Cancer</i> , 1979, 43, 2288-2296.	2.0	43
119	Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. <i>International Journal of Cancer</i> , 1990, 46, 878-883.	2.3	43
120	Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. <i>Cancer Immunology, Immunotherapy</i> , 1991, 32, 280-288.	2.0	43
121	Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa056.	0.4	43
122	Immunologic characterization of chronic lymphocytic leukemia cells. <i>Cancer</i> , 1977, 39, 1109-1118.	2.0	42
123	Purine Metabolites in Tumor-Derived Exosomes May Facilitate Immune Escape of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1602.	1.7	42
124	Suppression of cytokine-mediated Î²2-integrin activation on circulating neutrophils in critically ill patients. <i>Journal of Leukocyte Biology</i> , 1999, 66, 83-89.	1.5	41
125	Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 811-826.	1.5	41
126	Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 1991, 13, 15-21.	0.9	40

#	ARTICLE	IF	CITATIONS
127	Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1â€“Infected Apoptotic Cells. <i>Journal of Infectious Diseases</i> , 2016, 213, 1400-1409.	1.9	40
128	The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1029-1040.	1.5	40
129	Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5698.	1.8	40
130	CD44v3 protein-carrying tumor-derived exosomes in HNSCC patientsâ€™ plasma as potential noninvasive biomarkers of disease activity. <i>Onc Immunology</i> , 2020, 9, 1747732.	2.1	40
131	Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 623-629.	1.5	39
132	Usage of T-cell receptor VÎ² chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. <i>International Journal of Cancer</i> , 1993, 54, 383-390.	2.3	38
133	The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. <i>Wspolczesna Onkologia</i> , 2018, 2018, 38-40.	0.7	38
134	Proteomic profile of melanoma cellâ€“derived small extracellular vesicles in patientsâ€™ plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12063.	5.5	38
135	Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6234.	1.8	38
136	Use of Antibody to Membrane Adenosine Triphosphatase in the Study of Bacterial Relationships. <i>Journal of Bacteriology</i> , 1971, 105, 957-967.	1.0	38
137	Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. <i>Clinical Transplantation</i> , 1999, 13, 39-44.	0.8	37
138	Persistence of scleroderma-like phenotype in normal fibroblasts after prolonged exposure to soluble mediators from mononuclear cells. <i>Arthritis and Rheumatism</i> , 1986, 29, 54-64.	6.7	36
139	Harmonization of exosome isolation from culture supernatants for optimized proteomics analysis. <i>PLoS ONE</i> , 2018, 13, e0205496.	1.1	36
140	Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. <i>Oncoscience</i> , 2018, 5, 75-87.	0.9	36
141	Exosomes in acute myeloid leukemia inhibit hematopoiesis. <i>Current Opinion in Hematology</i> , 2018, 25, 279-284.	1.2	35
142	Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues. <i>Arthritis and Rheumatism</i> , 1988, 31, 1221-1229.	6.7	34
143	Bioprinting exosome-like extracellular vesicle microenvironments. <i>Bioprinting</i> , 2019, 13, e00041.	2.9	34
144	Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). <i>Journal of Molecular Medicine</i> , 2010, 88, 577-588.	1.7	33

#	ARTICLE	IF	CITATIONS
145	Immunobiology and immunotherapy of head and neck cancer. <i>Current Oncology Reports</i> , 2001, 3, 46-55.	1.8	32
146	Abnormalities in the p53 gene in tumors and cell lines of human squamous-cell carcinomas of the head and neck. <i>International Journal of Cancer</i> , 1993, 54, 322-327.	2.3	30
147	Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. <i>Molecular and Cellular Biochemistry</i> , 1999, 199, 209-215.	1.4	30
148	Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. <i>Oncogene</i> , 2000, 19, 514-525.	2.6	30
149	Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins. <i>Oncolmmunology</i> , 2019, 8, e1593808.	2.1	30
150	Simultaneous Inhibition of Glycolysis and Oxidative Phosphorylation Triggers a Multi-Fold Increase in Secretion of Exosomes: Possible Role of 2â€²,3â€²-cAMP. <i>Scientific Reports</i> , 2020, 10, 6948.	1.6	30
151	The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 241-258.	1.4	29
152	Divergent effects of FcÎ³RIIIA ligands on the functional activities of human natural killer cells in vitro. <i>European Journal of Immunology</i> , 1996, 26, 1199-1203.	1.6	28
153	Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. <i>Clinical Cancer Research</i> , 1998, 4, 1135-45.	3.2	28
154	HLA restriction and T-cell-receptor VÎ²2 gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. <i>International Journal of Cancer</i> , 1994, 57, 297-305.	2.3	27
155	Production of a Dendritic Cell-Based Vaccine Containing Inactivated Autologous Virus for Therapy of Patients with Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Vaccine Journal</i> , 2009, 16, 233-240.	3.2	26
156	Isolation of Biologically Active Exosomes from Plasma of Patients with Cancer. <i>Methods in Molecular Biology</i> , 2017, 1633, 257-265.	0.4	25
157	Signaling of Tumor-Derived sEV Impacts Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5066.	1.8	25
158	Cytokine Assays. <i>BioTechniques</i> , 2002, 33, S4-S15.	0.8	24
159	Mechanisms of T-cell protection from death by IRIX-2: a new immunotherapeutic. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 495-506.	2.0	24
160	Increased small extracellular vesicle secretion after chemotherapy via upregulation of cholesterol metabolism in acute myeloid leukaemia. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1800979.	5.5	24
161	Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. <i>British Journal of Cancer</i> , 2021, 125, 1677-1686.	2.9	24
162	In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. <i>Cancer Research</i> , 1988, 48, 6069-75.	0.4	24

#	ARTICLE	IF	CITATIONS
163	Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. <i>Advances in Experimental Medicine and Biology</i> , 1998, 451, 167-71.	0.8	24
164	Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. <i>Cancer Microenvironment</i> , 2015, 8, 201-207.	3.1	23
165	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and SÅ©zary syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 423-434.	2.0	23
166	Isolation of Exosomes for the Purpose of Protein Cargo Analysis with the Use of Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2017, 1654, 291-307.	0.4	22
167	Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression. <i>Experimental Hematology</i> , 2019, 76, 60-66.e2.	0.2	22
168	DPP4+ exosomes in AML patientsâ€™ plasma suppress proliferation of hematopoietic progenitor cells. <i>Leukemia</i> , 2021, 35, 1925-1932.	3.3	22
169	The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT). <i>Translational Cancer Research</i> , 2017, 6, S90-S92.	0.4	22
170	Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1992, 35, 694-699.	6.7	21
171	Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles. <i>Neuro-Oncology</i> , 2022, 24, 197-209.	0.6	21
172	Microvessel density in head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1845-1851.	0.8	20
173	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. , 2016, 4, 24.		19
174	Pneumococcal Extracellular Vesicles Modulate Host Immunity. <i>MBio</i> , 2021, 12, e0165721.	1.8	19
175	Extravasation of antitumor effector cells. <i>Invasion & Metastasis</i> , 1992, 12, 128-46.	0.5	19
176	Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. <i>Cancer Immunology, Immunotherapy</i> , 1997, 44, 137-149.	2.0	18
177	Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. , 1999, 82, 532-537.		18
178	Validation of plasma-derived small extracellular vesicles as cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 719-720.	12.5	18
179	Exosomes in Breast Cancer â€™ Mechanisms of Action and Clinical Potential. <i>Molecular Cancer Research</i> , 2021, 19, 935-945.	1.5	18
180	Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2021, 61, 16-26.	3.2	18

#	ARTICLE	IF	CITATIONS
181	NOX activation in reactive astrocytes regulates astrocytic LCN2 expression and neurodegeneration. <i>Cell Death and Disease</i> , 2022, 13, 371.	2.7	18
182	Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E494-501.	0.9	17
183	Imbalance of t-cell subpopulations does not result in defective helper function in chronic lymphocytic leukemia. <i>Cancer</i> , 1981, 48, 1754-1760.	2.0	16
184	Comparison of in Vivo and in Vitro Prostaglandin E ₂ Production by Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 1994, 111, 189-196.	1.1	16
185	Measurement of Cytotoxic Activity of NK/LAK Cells. , 2001, Chapter 7, Unit 7.18.		16
186	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 13-20.	1.4	16
187	IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3731-3746.	1.0	16
188	mRNA and miRNA Profiles of Exosomes from Cultured Tumor Cells Reveal Biomarkers Specific for HPV16-Positive and HPV16-Negative Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8570.	1.8	16
189	Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 305-321.	0.4	16
190	Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids. <i>Hno</i> , 2020, 68, 100-105.	0.4	15
191	Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. <i>Transplantation Proceedings</i> , 1988, 20, 342-3.	0.3	15
192	Human Natural Killer Cells in Health and Disease. <i>BioDrugs</i> , 1994, 1, 56-66.	0.7	14
193	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 1008-1016.	0.9	14
194	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1133-1141.	2.0	14
195	Adenosine receptors regulate exosome production. <i>Purinergic Signalling</i> , 2020, 16, 231-240.	1.1	14
196	Stimulatory role of exosomes in the context of therapeutic anticancer vaccines. <i>Biotarget</i> , 2017, 1, 5-5.	0.5	13
197	Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. <i>Blood</i> , 1993, 81, 2085-92.	0.6	13
198	Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 15-21.	2.0	12

#	ARTICLE	IF	CITATIONS
199	The Role of Tumor-Derived Exosomes (TEX) in Shaping Anti-Tumor Immune Competence. <i>Cells</i> , 2021, 10, 3054.	1.8	12
200	Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. <i>Anticancer Research</i> , 1996, 16, 2357-64.	0.5	12
201	Interleukin 2 Receptors on Squamous Cell Carcinomas of the Head and Neck. <i>Acta Oto-Laryngologica</i> , 1992, 112, 370-375.	0.3	11
202	Human gastric carcinoma transduced with theIL-2 gene: Increased sensitivity to immune effector cellsin vitro andin vivo. , 1997, 72, 174-183.		11
203	Novel TGFÎ² Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Antiâ€“PD-L1 Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1102-1111.	1.9	11
204	Sensorineural Hearing Loss From Quinolinic Acid. <i>Laryngoscope</i> , 1994, 101, 176-181.	1.1	10
205	Proteomic Analysis of Plasma-Derived Exosomes in Defining Their Role as Biomarkers of Disease Progression, Response to Therapy and Outcome. <i>Proteomes</i> , 2019, 7, 27.	1.7	10
206	Role of exosome-associated adenosine in promoting angiogenesis. <i>Vessel Plus</i> , 2020, 2020, .	0.4	10
207	Ionizing Radiation and TNF-a and Stimulated Expression of a1-Antichymotrypsin Gene in Human Squamous Carcinoma Cells. <i>Acta OncolÃ³gica</i> , 1998, 37, 475-478.	0.8	9
208	Human regulatory T cells (Treg) and their response to cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 215-228.	0.4	9
209	Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2041.	1.7	9
210	Lymphokine-activated killer cell activity in patients with primary and metastatic malignant liver tumors. <i>Hepatology</i> , 1989, 10, 221-227.	3.6	8
211	Adoptive Immunotherapy of Cancer. <i>BioDrugs</i> , 1994, 2, 13-22.	0.7	8
212	Polyfunctionality of CD4+ TÃ³lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 392-402.	1.0	8
213	The biology of human natural killer cells. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 1990, 26, 335-48.	0.2	8
214	Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. <i>Transplantation Proceedings</i> , 1988, 20, 347-50.	0.3	8
215	Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells. , 1997, 18, 1-6.		7
216	Lymphocyte homeostasis and the antitumor immune response. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 369-378.	1.3	7

#	ARTICLE	IF	CITATIONS
217	A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. <i>Journal of Clinical Oncology</i> , 2007, 25, 3011-3011.	0.8	7
218	Production of a glycosaminoglycan stimulatory factor by cloned human T lymphocytes activated in vitro. <i>Arthritis and Rheumatism</i> , 1986, 29, 1071-1077.	6.7	6
219	Isolation of Human NK Cells and Generation of LAK Activity. , 2001, Chapter 7, Unit 7.7.		6
220	Lymphoma exosomes reprogram the bone marrow. <i>Blood</i> , 2018, 131, 1635-1636.	0.6	6
221	Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana's healthy population. <i>Scientific Reports</i> , 2020, 10, 2814.	1.6	6
222	IFN γ Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3661-3673.	3.2	6
223	Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. <i>Transplantation Proceedings</i> , 1991, 23, 3047-51.	0.3	6
224	Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. <i>In Vivo</i> , 1991, 5, 553-9.	0.6	6
225	Proteomic and Metabolomic Profiles of T Cell-Derived Exosomes Isolated from Human Plasma. <i>Cells</i> , 2022, 11, 1965.	1.8	6
226	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 1997, 173, 197-201.	1.4	5
227	Small Extracellular Vesicles from Head and Neck Squamous Cell Carcinoma Cells Carry a Proteomic Signature for Tumor Hypoxia. <i>Cancers</i> , 2021, 13, 4176.	1.7	5
228	Circulating Exosomes Carrying an Immunosuppressive Cargo Interfere with Adoptive Cell Therapy in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1609-1609.	0.6	5
229	Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes. <i>Translational Cancer Research</i> , 2017, 6, S1406-S1408.	0.4	5
230	Cytokine assays. <i>BioTechniques</i> , 2002, Suppl, 4-8, 10, 12-5.	0.8	5
231	Discrepancies between in vivo and in vitro responses to <i>Candida</i> antigen in patients with progressive systemic sclerosis (PSS; scleroderma). <i>Journal of Clinical Immunology</i> , 1981, 1, 250-256.	2.0	4
232	Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. <i>Melanoma Research</i> , 2021, 31, 472-475.	0.6	4
233	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. <i>Experientia Supplementum</i> (2012), 2022, 113, 89-106.	0.5	4
234	Partial purification and characterization of a novel human factor that augments the expression of class I MHC antigens on tumour cells. <i>Journal of Biosciences</i> , 1996, 21, 13-25.	0.5	3

#	ARTICLE	IF	CITATIONS
235	RE: Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv276.	3.0	3
236	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020, 60, 1867-1872.	0.8	3
237	Impact of contracted manufacturing organization protocols on operations in an academically based Current Good Manufacturing Practice facility. <i>Cytotherapy</i> , 2022, 24, 32-36.	0.3	3
238	Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2938-2938.	0.6	3
239	Identification and partial purification of a human natural killer cell proliferation-inducing factor. <i>Journal of Biosciences</i> , 1996, 21, 455-469.	0.5	2
240	Expression and signaling of Toll-like receptor 4 (TLR4) and MyD88 in ovarian carcinoma cells. <i>Journal of Clinical Oncology</i> , 2009, 27, e16508-e16508.	0.8	2
241	Profiling of plasma-derived extracellular vesicles cargo for diagnosis of pancreatic malignancy. <i>Annals of Translational Medicine</i> , 2017, 5, 501-501.	0.7	2
242	Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes. <i>Immunology Series</i> , 1989, 48, 139-57.	0.3	2
243	Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016, 36, 611-5.	0.5	2
244	Breast Cancer Cell-Derived Adenosine Enhances Generation and Suppressor Function of Human Adaptive Regulatory T Cells. <i>Journal of Personalized Medicine</i> , 2021, 11, 754.	1.1	1
245	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. <i>International Journal of Cancer</i> , 1996, 68, 276-284.	2.3	1
246	Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells. <i>Molecular Carcinogenesis</i> , 1997, 18, 1-6.	1.3	1
247	The number of intratumoral dendritic cells and β -chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. , 2001, 91, 2136.		1
248	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1649-1649.	0.6	1
249	Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2. <i>Progress in Clinical and Biological Research</i> , 1987, 244, 213-22.	0.2	1
250	Interplay between exosomes and autophagy: Are they partners in crime?. , 2020, , 197-212.		0
251	CD8+ T cell Recognition of Polymorphic Wild Type Sequence p53 65-73 Peptides in Squamous Cell Carcinoma of the Head and Neck. <i>FASEB Journal</i> , 2008, 22, 1079.15.	0.2	0
252	The Role of Immune Effector Cells in Immunotherapy of Head and Neck Cancer.. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 1995, 46, 71-83.	0.0	0

#	ARTICLE	IF	CITATIONS
253	Immunotherapy for acute leukemia. <i>Aging</i> , 2015, 7, 354-355.	1.4	0
254	Diversity of Extracellular Vesicles (EV) in Plasma of Cancer Patients. <i>Physiology</i> , 0, , .	4.0	0
255	Serum and tissue banks for biological markers. <i>Immunology Series</i> , 1990, 53, 55-68.	0.3	0